Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis

J Bone Miner Res. 2011 Sep;26(9):1989-96. doi: 10.1002/jbmr.362. Epub 2011 Jun 30.

Abstract

Much knowledge has accrued since the 2001 American College of Rheumatology (ACR) guidelines were published to assist clinicians in the prevention and treatment of glucocorticoid-induced osteoporosis (GIO). Therefore, the ACR undertook a comprehensive effort to review the literature and update the GIO guidelines [Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-1526]. Herein, we review the new guidelines for JBMR readers, highlighting the changes introduced by the 2010 publication. We discuss several patient scenarios for which the new treatment guidelines do not apply, or for which our committee interprets existing literature differently and suggests an alternative approach.

Publication types

  • Review

MeSH terms

  • Diphosphonates / therapeutic use
  • Fractures, Bone / complications
  • Fractures, Bone / drug therapy
  • Glucocorticoids / adverse effects*
  • Hormone Replacement Therapy
  • Humans
  • Osteoporosis / chemically induced
  • Osteoporosis / complications
  • Osteoporosis / drug therapy*
  • Osteoporosis / prevention & control*
  • Uncertainty*

Substances

  • Diphosphonates
  • Glucocorticoids